Chemical biology
has revealed the importance of sialic acids as
a major signal in physiology and disease. The terminal modification
α-2,6-sialic acid is controlled by the enzymes ST6GAL1 and ST6GAL2.
Dysregulation of this glycan impacts immunological recognition and
cancer development. microRNAs (miRNA, miR), noncoding RNAs that downregulate
protein expression, are important regulators of glycosylation. Using
our recently developed high-throughput fluorescence assay (miRFluR),
we comprehensively mapped the miRNA regulatory landscape of α-2,6-sialyltransferases
ST6GAL1 and ST6GAL2. We found, contrary to expectations, the majority
of miRNAs upregulate ST6GAL1 and α-2,6-sialylation in a variety
of cancer cells. In contrast, miRNAs that regulate ST6GAL2 were predominantly
downregulatory. Mutational analysis identified direct binding sites
in the 3′-untranslated region (UTR) responsible for upregulation,
confirming it is a direct effect. The miRNA binding proteins AGO2
and FXR1 were required for upregulation. Our results upend common
assumptions surrounding miRNA, arguing that upregulation by these
noncoding RNA is common. Indeed, for some proteins, upregulation may
be the dominant function of miRNA. Our work also suggests that upregulatory
miRNAs enhance overexpression of ST6GAL1 and α-2,6-sialylation,
providing another potential pathway to explain the dysregulation observed
in cancer and other disease states.